Phase 2 N=20 Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
IgG4-RD
Primary: Proportion of Patients With an Improvement in IgG4-RD Activity — 12; 4; 2; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Zanubrutinib in Patients With IgG4-Related Disease
IgG4 Related Disease
Primary: Volume of the Submandibular Glands on PET-MRI — 12.7; 9.34; -3.37 cm^3 — p=< 0.001
Phase 2 N=30 Rituximab in IgG4-RD: A Phase 1-2 Trial
Retroperitoneal Fibrosis · Autoimmune Pancreatitis · Sialadenitis
Primary: IgG4-RD RI Score at Baseline and Six Months After Rituxan Treatment — 11; 1 units on a scale
Phase 2 N=10 Safety and Efficacy of Abatacept in IgG4-Related Disease
IgG4-related Disease
Primary: Treatment Response — 3 Participants
Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
N/A N=118 Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
Churg-Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis
Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESI) — 69; 26; 42 Participants
Phase 4 N=16 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Phase 2 N=30 Tocilizumab for Patients With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of Patients That Have Achieved Complete Remission of Disease — 17; 4 Participants — p=0.0301
N/A N=60 Auto-antibodies Prevalence and CD1 Role in Gaucher Disease
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Phase 2 N=9 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
N/A N=120 Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Churg-Strauss Syndrome · Eosinophilic Asthma · Eosinophilic Esophagitis
Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants
Phase 2 N=20 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Phase 2 N=9 Imatinib in Systemic Sclerosis
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Phase 3 N=25 Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
Primary Immune Deficiency
Primary: IgG Trough Level — 1.09; 1.11 Ratio of Geometric Means
Phase 3 N=6 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
Autoimmune Autonomic Ganglionopathy (AAG)
Primary: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) — 42.5; -12.3 mmHg
N/A N=133 Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Infections After Lung Transplant
Primary: The Primary Outcome Will be the Total Number of Days With Pneumonia. — 1714; 51 Number of days
N/A N=120 IgG-mediated Food Test for Weight Loss
Overweight and Obesity
Primary: Weight (kg) — 80; 76.6; 74.7; 75 kilograms
Phase 3 N=12 An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
Primary Immunodeficiency Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs — 12; 3; 12 Participants
Phase 2 N=27 Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
Diffuse Cutaneous Systemic Sclerosis
Primary: Number of Participants With at Least One Adverse Event (AE) for IgPro20 — 9; 9 Participants
Phase 2 N=57 Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
Macular Degeneration
Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…
Phase 2 N=14 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Phase 2 N=54 Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Immunoglobulin A (IgA) Nephropathy
Primary: Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9 — -24.7; -16.5; -30.6; -38.5 gram per gram (g/g) — p=0.6837
Phase 3 N=208 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy
Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…
Phase 2 N=12 Daratumumab in Treatment of PGNMID and C3 GN
Membranoproliferative Glomerulonephritis
Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events
Phase 3 N=20 Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Progressive IgA Nephropathy · Proteinuria
Primary: Number of Subjects With a Complete or Partial Response to Treatment — 8 Participants
Phase 2 N=27 IVIG-eye Drops Treatment for Dry Eye Disease
Dry Eye
Primary: Tolerability: The Primary Tolerability Endpoint is the Test Substance Tolerance (Visual Analog Scale) at 8 Weeks (56 Days) — 100; 100 score on a scale — p=1.000
Phase 2 N=15 Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
Anti-Glomerular Basement Membrane Antibody Disease
Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants
Phase 2 N=30 A Study of Imlifidase in Patients With Guillain-Barré Syndrome
Guillain-Barré Syndrome (GBS)
Primary: Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 1 Grade — 6.0 days
Phase 2 N=45 Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Remission of Vasculitis — 95 Percentage of participants
N/A N=165 Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants